Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sysmex Corporation Announces Executive Changes
Currently, Obe is chairman and CEO of Sysmex America, Inc. John Kershaw, who is presently serving as president and chief operating officer (COO) of Sysmex America, will be
Currently, Obe is chairman and CEO of Sysmex America, Inc. John Kershaw, who is presently serving as president and chief operating officer (COO) of Sysmex America, will be
According to BioImagene, Virtuoso is a comprehensive suite of web-based software applications that work with its iScan slide scanners to provide an end-to-end workflow solution. It is a
Under the licensing agreement, Quest Diagnostics will have rights to use and sell products and services incorporating the MGB Probe technology. Terms of the end user licensing agreement
The application for the drug was submitted by Ranbaxy, from its Ohm Laboratories manufacturing facility, at New Jersey, US. The Office of Generic Drugs, FDA, had determined the
The asset purchase agreement with Antigua Medical Services calls for the sale of portable nuclear imaging cameras, vans and related equipment, and the assignment of certain customer contracts
Ms Turner brings to Tyrx over 25 years of sales and management experience in the medical device space through her numerous positions of increasing responsibility with Guidant, now
Mr Elam has been appointed to fill a seat previously held by Cory Berkland. Mr Elam is a former member of the executive management team of Nektar Therapeutics
Dr Gamzu has more than 35 years of pharmaceutical and biotechnology industry experience and has held a number of senior executive positions in those industries including CEO of
ArQule and Daiichi Sankyo have previously signed a license, co-development and co-commercialization agreement to co-develop ARQ 197 in the US, Europe, South America and the rest of the
Mr Ede continues to serve on Mindray’s board of directors but does not serve on any of the board’s committees. Ms Hsu will immediately begin working closely with